Presenting how data transformation is measured as part of the SAFE Data Standard, which data variables influence the rating and, how the appropriate level of data transformation is calculated.
Stephen Bamford
Advertisement
Head of Clinical Data Standards & Transparency, The Janssen Pharmaceutical Companies of Johnson & Johnson
Articles by Stephen Bamford
Advertisement
Latest Updated Articles
- Sharing Anonymized and Functionally Effective (SAFE) Data Standard for Safely Sharing Rich Clinical Trial Data
Published: April 8th 2022 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
2
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
3
ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA
4
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
5